Prandin and Yonsa

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Abiraterone may increase the blood levels of repaglinide. You may be more likely to experience side effects such as hypoglycemia, or low blood sugar, that can sometimes occur with the use of repaglinide. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and palpitation. The risk of other serious but uncommon side effects such as fluid retention, macular edema (swelling in the back of the eye), new or worsening heart failure, bone fractures, anemia, and liver problems may also be increased. You may need a dose adjustment or more frequent monitoring of your blood sugar and other tests to safely use both medications. Contact your doctor immediately if you experience blurred vision or other visual abnormalities; excessive or rapid weight gain; swelling in the ankles or legs; shortness of breath or difficulty breathing; unusual tiredness; chest pain or tightness; or worsening of existing heart problems. You should also seek prompt medical attention if you develop signs and symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme. In 12 healthy volunteers given the potent CYP450 2C8 inhibitor gemfibrozil (600 mg twice daily) for two days prior to coadministration with a single 0.25 mg dose of repaglinide on day 3, mean repaglinide systemic exposure (AUC) increased by 8.1-fold and elimination half-life (T 1/2) from 1.3 to 3.7 hours. When 160 mg twice daily of trimethoprim, a relatively weak CYP450 2C8 inhibitor, was given similarly in a study of nine healthy volunteers, mean peak plasma concentration (Cmax) and AUC of repaglinide increased by 41% and 61%, respectively, and T 1/2 increased from 0.9 to 1.1 hours. Another CYP450 2C8 inhibitor, deferasirox, given at 30 mg/kg/day for 4 days increased the Cmax and AUC of a single 0.5 mg dose of repaglinide by 62% and 131%, respectively. Further pharmacokinetic changes may be observed if there is concurrent inhibition of CYP450 3A4, which also contributes to the metabolism of repaglinide.

MANAGEMENT: Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with a CYP450 2C8 inhibitor. Patients should regularly monitor their blood sugar and learn how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation. The dosage of repaglinide may require adjustment if an interaction is suspected. Likewise, patients should be observed for potential loss of glycemic control following discontinuation of the CYP450 2C8 inhibitor, and the repaglinide dosage adjusted as necessary.

Prandin

Generic Name: repaglinide

Brand name: Prandin

Synonyms: n.a.

What is Prandin?

Yonsa

Generic Name: abiraterone

Brand name: Yonsa, Zytiga

Synonyms: n.a.

What is Yonsa?